Nephros Stock Executives

NEPH
 Stock
  

USD 1.47  0.03  2.00%   

Nephros employes about 34 people. The company is managed by 10 executives with total tenure of roughly 63 years, averaging almost 6.0 years of service per executive having 3.4 employees per reported executive. Examination of Nephros management performance can provide insight into the company performance. Note, employee sentiment is becoming a valuable factor that investors use to determine the amount of risk that may be associated with Nephros future performance.
Additionally, see Stocks Correlation.
  
Refresh
  Daron Evans  CEO
CEO and President Acting CFO, Director and Member of Audit Committee

Nephros Management Team Effectiveness

Nephros has return on total asset (ROA) of (14.98) % which means that it has lost $14.98 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (25.51) %, meaning that it created substantial loss on money invested by shareholders. Nephros management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities.

Nephros Workforce Comparison

Nephros is considered to be number one stock in number of employees category among related companies. The total workforce of Medical Instruments & Supplies industry is now estimated at about 117,629. Nephros adds roughly 34.0 in number of employees claiming only tiny portion of all equities under Medical Instruments & Supplies industry.

Nephros Profit Margins

The company has Profit Margin (PM) of (39.47) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (41.67) %, which suggests for every $100 dollars of sales, it generated a net operating loss of -0.42.

Nephros Insider Trading

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Nephros insiders, such as employees or executives, is commonly permitted as long as it does not rely on Nephros' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Nephros insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Nephros Benchmark Summation

Operator
The output start index for this execution was zero with a total number of output elements of sixty-one. Nephros Price Series Multiplication is a cross multiplication of Nephros price series and its benchmark/peer.
.

Nephros Notable Stakeholders

A Nephros stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Nephros often face trade-offs trying to please all of them. Nephros' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Nephros' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Daron Evans - CEO and President Acting CFO, Director and Member of Audit CommitteeProfile
Andrew Astor - CFOProfile
Malcom Persen - DirectorProfile
Thomas Gwydir - DirectorProfile
Paul Mieyal - DirectorProfile
Alisa Lask - DirectorProfile
Matthew Rosenberg - DirectorProfile
Moshe Pinto - DirectorProfile
Arthur Amron - Independent DirectorProfile
Oliver Spandow - DirectorProfile

About Nephros Management Performance

The success or failure of an entity such as Nephros often depends on how effective the management is. Nephros management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Nephros management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Nephros management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Please read more on our stock advisor page.
Nephros, Inc. develops and sells high performance water solutions to the medical and commercial markets in the United States. The company operates in three segments Water Filtration, Pathogen Detection, and Renal Products. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. The company also develops and sells real-time water testing systems to provide actionable data on waterborne pathogens and medical device products for patients with renal disease, including a 2nd generation hemodiafiltration system for the treatment of patients with end stage renal disease. In addition, it offers water filters that improve the taste and odor of water, as well as reduce biofilm, bacteria, and scale build-up in downstream equipment under the Nephros and AETHER brands for the food service, hospitality, convenience store, and health care markets. The company was incorporated in 1997 and is headquartered in South Orange, New Jersey.
The data published in Nephros' official financial statements usually reflect Nephros' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Nephros. For example, before you start analyzing numbers published by Nephros accountants, it's critical to develop an understanding of what Nephros' liquidity, profitability, and earnings quality are in the context of the Healthcare space in which it operates.
Please note, the presentation of Nephros' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Nephros' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Nephros' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Nephros. Please utilize our Beneish M Score to check the likelihood of Nephros' management to manipulate its earnings.

Nephros Workforce Analysis

Traditionally, organizations such as Nephros use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Nephros within its industry.

Nephros Manpower Efficiency

Return on Nephros Manpower

Revenue Per Employee305.9 K
Revenue Per Executive1 M
Net Loss Per Employee120.9 K
Net Loss Per Executive411 K
Working Capital Per Employee24.9 K
Working Capital Per Executive84.8 K
Additionally, see Stocks Correlation. Note that the Nephros information on this page should be used as a complementary analysis to other Nephros' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.

Complementary Tools for Nephros Stock analysis

When running Nephros price analysis, check to measure Nephros' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nephros is operating at the current time. Most of Nephros' value examination focuses on studying past and present price action to predict the probability of Nephros' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Nephros' price. Additionally, you may evaluate how the addition of Nephros to your portfolios can decrease your overall portfolio volatility.
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Go
Money Managers
Screen money managers from public funds and ETFs managed around the world
Go
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Go
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Fund Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Go
ETF Directory
Find actively traded Exchange Traded Funds (ETF) from around the world
Go
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Go
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Go
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Go
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Go
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Is Nephros' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Nephros. If investors know Nephros will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Nephros listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
15.8 M
Quarterly Revenue Growth YOY
-0.2
Return On Assets
-0.2
Return On Equity
-0.37
The market value of Nephros is measured differently than its book value, which is the value of Nephros that is recorded on the company's balance sheet. Investors also form their own opinion of Nephros' value that differs from its market value or its book value, called intrinsic value, which is Nephros' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Nephros' market value can be influenced by many factors that don't directly affect Nephros' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Nephros' value and its price as these two are different measures arrived at by different means. Investors typically determine Nephros value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Nephros' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.